Markets:

Overview

News

Currencies

International

Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

18.53 +0.15 (+0.82%)

Streaming Delayed Price Updated: 12:33 PM EST, Feb 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

34 35 Next >

Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT

July 18, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

July 18, 2025

From The Schall Law Firm

Via Business Wire

Top stock movements in today's session. ↗

July 18, 2025

Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

Sarepta Draws Wall Street Ire After Third Patient Death This Year: Analyst Says ‘Deeply Concerning’ The Incident Wasn’t Reported Earlier ↗

July 18, 2025

Via Stocktwits

Stocks Slip As Netflix Fails To Impress, Bitcoin Eyes Negative Week: What's Moving Markets Friday? ↗

July 18, 2025

It’s a cautious end to the week on Wall Street, as earnings from Netflix Inc. (NASDAQ:NFLX) failed to impress investors.

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

July 18, 2025

Via Benzinga

FDA Is Reportedly ‘Taking A Hard Look’ To Evaluate Whether Sarepta’s Gene Therapy Elevidys Should Remain On The Market ↗

July 18, 2025

The FDA had already been investigating two earlier deaths linked to Elevidys.

Via Stocktwits

Topics Death

Friday's session: top gainers and losers ↗

July 18, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT

July 18, 2025

From Pomerantz LLP

Via GlobeNewswire

Sarepta's Setback Deepens With Another Gene Therapy Fatality ↗

July 18, 2025

Sarepta's gene therapy pipeline faces renewed scrutiny after a third patient death and FDA plans for a black box warning on Elevidys.

Via Benzinga

Gapping stocks in Friday's session ↗

July 18, 2025

Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

Sarepta Therapeutics Crashes 26% After A Third Gene Therapy Patient Dies ↗

July 18, 2025

The move wiped out all of the gains Sarepta lodged Thursday after announcing its restructuring plans.

Via Investor's Business Daily

Topics Death Stocks

Netflix, BlackSky Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

July 18, 2025

Via Benzinga

Get insights into the top gainers and losers of Friday's pre-market session. ↗

July 18, 2025

The US market is yet to commence its session on Friday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

July 18, 2025

From Schall Law

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 18, 2025

Via Benzinga

Sarepta Therapeutics Stock Plunges Over 30% In Friday Pre-Market: What's Going On ↗

July 18, 2025

Shares of Sarepta Therapeutics (NASDAQ: SRPT) plunged 26.85% in Friday pre-market after a clinical trial participant died following treatment with a gene therapy, marking the third death linked to the...

Via Benzinga

Topics Death

Why Interactive Brokers Group Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket ↗

July 18, 2025

Via Benzinga

ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT

July 17, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

Sarepta Therapeutics' Reorganization Boosts Investor Confidence ↗

July 17, 2025

Sarepta agrees to FDA's black box warning and announces major restructuring, including job cuts and cost-saving measures to meet 2027 goals.

Via Benzinga

AAR, Lucid Group, Monarch Casino & Resort And Other Big Stocks Moving Higher On Thursday ↗

July 17, 2025

Via Benzinga

Assessing Sarepta Therapeutics: Insights From 35 Financial Analysts ↗

July 17, 2025

Via Benzinga

Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT

July 17, 2025

Via TheNewswire.com

Topics Fraud Lawsuit

Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT

July 17, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Fraud Lawsuit

What's going on in today's pre-market session ↗

July 17, 2025

Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

July 17, 2025

Via Benzinga

Why Sarepta Therapeutics Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket ↗

July 17, 2025

Via Benzinga

Sarepta To Lay Off 500 Employees After Two Patient Deaths; Shares Catapult ↗

July 16, 2025

The company is also restructuring with the hopes of saving $400 million in expenses.

Via Investor's Business Daily

Topics Death Earnings Government

Sarepta Surges After-Hours As It Slashes 500 Jobs Amid FDA Black Box Warning For Gene Therapy — Retail Eyes Rebound ↗

July 16, 2025

The company also updated investors on its ELEVIDYS gene therapy label, agreed to an FDA-requested black box warning, and outlined plans to resume dosing in non-ambulant patients.

Via Stocktwits

Topics Death

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm

July 16, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.